18 F.4th 1333
Fed. Cir.2021Background
- Biogen owns U.S. Patent No. 8,399,514 claiming a method of treating multiple sclerosis (MS) by orally administering dimethyl fumarate (DMF) at about 480 mg/day (DMF480). Priority was claimed to a February 8, 2007 provisional (the ’921 application).
- The original 2007 specification focused on Nrf2 screening and drug-discovery methods for many neurological disorders; it mentions DMF repeatedly but contains a single explicit reference to DMF480 as part of broader dosage ranges (100–1,000 mg/day; 480–720 mg/day).
- Biogen later obtained Phase III clinical data showing DMF480 efficacy, amended claims and inventorship (adding Dr. O’Neill), and obtained the ’514 patent in 2013 claiming DMF480 for MS treatment.
- Mylan filed an ANDA for a generic DMF product; Biogen sued for infringement and Mylan counterclaimed that the ’514 claims were invalid for lack of written description under 35 U.S.C. § 112.
- After a bench trial the district court found, based on the specification and witness credibility findings, that the 2007 disclosure did not show possession of a therapeutically effective DMF480 dose for MS as of the priority date; the court held the asserted claims invalid.
- The Federal Circuit (majority) affirmed, holding the district court did not clearly err in finding Mylan proved invalidity for lack of written description; Judge O’Malley dissented, arguing the court misapplied judicial estoppel and conflated clinical efficacy with therapeutic effect.
Issues
| Issue | Plaintiff's Argument (Biogen) | Defendant's Argument (Mylan) | Held |
|---|---|---|---|
| Whether the 2007 specification satisfies §112 written-description for a therapeutically effective DMF480 dose to treat MS | Specification discloses DMF repeatedly, expressly lists 480–720 mg/day, defines “therapeutically effective” (includes biological and clinical indicia), and anchors 480 to known efficacious 720 mg | Specification only mentions DMF480 once as part of broad ranges; focus was exploratory Nrf2 screening, not clinical dosing; inventors lacked possession of DMF480 as of 2007 | Affirmed: district court not clearly erroneous — written-description lacking for DMF480 species; claims invalid under §112 |
| Whether later Phase III clinical data can supply written-description support or cure a lack of possession as of the priority date | Later clinical proof of efficacy reflects inventors’ conception and supports claim scope (Biogen emphasizes post‑filing development) | Written-description is judged as of filing/priority date; later clinical results cannot supply disclosure that was absent in 2007 | Held for Mylan: later clinical data irrelevant to written-description inquiry; priority-date possession required |
| Whether the specification contains sufficient "blaze marks" to single out DMF480 within broad genus/ranges | Column 18 explicitly discloses the 480–720 mg/day range, which points to the claimed 480 mg/day species | Column 18 lists many overlapping ranges and even ineffective doses; single, passing range reference does not reasonably convey possession of the claimed species | Held: court viewed the single mention as insufficient to show possession; district court’s blaze‑marks assessment not clearly erroneous |
| Whether Biogen was judicially estopped from distinguishing clinical efficacy from therapeutic effect (and whether that distinction mattered) | Distinguish clinical efficacy (Phase III endpoints vs. standard-of-care comparisons) from therapeutic effect (prevention, delay, biological outcomes); written description requires only therapeutic-effect disclosure | Mylan treated Biogen’s earlier IPR/obviousness positions as inconsistent and argued a POSA wouldn’t expect DMF480 to be effective; district court found Biogen’s arguments not persuasive | Majority: treated therapeutic/clinical distinction as factual and held district court’s findings (including credibility) were not clearly erroneous; dissent would remand because of judicial‑estoppel error |
Key Cases Cited
- Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (en banc) (written‑description "possession" requirement and disclosure hallmark)
- Nuvo Pharm. (Ireland) Designated Activity Co. v. Dr. Reddy’s Laboratories Inc., 923 F.3d 1368 (Fed. Cir. 2019) (written description requires disclosure supporting claimed therapeutic result)
- Vas‑Cath Inc. v. Mahurkar, 935 F.2d 1555 (Fed. Cir. 1991) (possession as of filing ties to priority-date entitlement)
- In re Ruschig, 379 F.2d 990 (C.C.P.A. 1967) (blaze‑marks doctrine for singling out species from a genus)
- Amgen Inc. v. Sanofi, 872 F.3d 1367 (Fed. Cir. 2017) (written-description judged by state of the art as of priority date)
- Novozymes A/S v. DuPont Nutrition Biosciences APS, 723 F.3d 1336 (Fed. Cir. 2013) (need for blaze marks in laundry‑list disclosures)
- Evans v. Eaton, 20 U.S. 356 (1822) (historical purpose of written description: put public on notice of claimed invention)